A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine kinase inhibitor dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of esophagus.
Hyo Song Kim
No relevant relationships to disclose
Han Sang Kim
No relevant relationships to disclose
Jong-Mu Sun
No relevant relationships to disclose
Myung-Ju Ahn
No relevant relationships to disclose
Keunchil Park
No relevant relationships to disclose
Hoon-Gu Kim
No relevant relationships to disclose
Ik-Joo Chung
No relevant relationships to disclose
Jong-Seok Lee
No relevant relationships to disclose
Se-Hoon Lee
No relevant relationships to disclose
Kyung Hee Lee
No relevant relationships to disclose
Dae Joon Kim
No relevant relationships to disclose
Hye Ryun Kim
No relevant relationships to disclose
Joo-Hang Kim
No relevant relationships to disclose
Byoung Chul Cho
No relevant relationships to disclose